To enhance the robustness of our findings, validation with larger gene panels, including genes involved in cell cycle regulation (CDKN2A and RB1), chromatin remodeling (KDM6A, ARID1A, and STAG2), DNA repair (ERCC2), tumor suppression (MTAP), and metabolic pathways (PPARG), as well as expanded cohorts, is warranted. The gene discussed is RB1; the disease is neoplasm.